Zacks Research Weighs in on STERIS’s Q3 Earnings (NYSE:STE)

STERIS plc (NYSE:STE) – Equities researchers at Zacks Research boosted their Q3 2025 EPS estimates for shares of STERIS in a research note issued to investors on Tuesday, January 21st. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings of $2.31 per share for the quarter, up from their prior forecast of $2.30. The consensus estimate for STERIS’s current full-year earnings is $9.10 per share. Zacks Research also issued estimates for STERIS’s FY2025 earnings at $9.08 EPS, Q1 2026 earnings at $2.27 EPS, Q2 2026 earnings at $2.37 EPS, Q3 2026 earnings at $2.54 EPS, Q4 2026 earnings at $2.81 EPS, FY2026 earnings at $9.99 EPS, Q1 2027 earnings at $2.48 EPS, Q2 2027 earnings at $2.59 EPS, Q3 2027 earnings at $2.63 EPS and FY2027 earnings at $10.35 EPS.

STERIS (NYSE:STE) last issued its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 EPS for the quarter, beating analysts’ consensus estimates of $2.12 by $0.02. The company had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.33 billion. STERIS had a return on equity of 13.78% and a net margin of 8.02%. STERIS’s revenue was up 7.3% on a year-over-year basis. During the same period last year, the business posted $2.03 earnings per share.

Several other research analysts have also issued reports on STE. StockNews.com lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. Stephens restated an “overweight” rating and set a $260.00 price objective on shares of STERIS in a research note on Thursday, November 7th. JMP Securities restated a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a report on Monday, November 18th. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a report on Friday, November 8th. Finally, Piper Sandler raised STERIS from a “neutral” rating to an “overweight” rating and upped their price target for the company from $230.00 to $260.00 in a report on Thursday, October 24th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, STERIS currently has an average rating of “Moderate Buy” and an average target price of $262.50.

STERIS Stock Up 0.7 %

Shares of NYSE STE opened at $218.54 on Thursday. The business has a 50-day moving average of $211.68 and a 200-day moving average of $224.74. The firm has a market capitalization of $21.57 billion, a price-to-earnings ratio of 49.89 and a beta of 0.84. The company has a current ratio of 2.41, a quick ratio of 1.55 and a debt-to-equity ratio of 0.33. STERIS has a 12 month low of $197.82 and a 12 month high of $248.24.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Ashton Thomas Securities LLC acquired a new stake in shares of STERIS during the 3rd quarter worth about $25,000. Central Pacific Bank Trust Division acquired a new position in STERIS in the third quarter valued at $28,000. Quarry LP acquired a new position in STERIS in the 3rd quarter valued at about $67,000. Asset Dedication LLC grew its stake in shares of STERIS by 54.8% in the 3rd quarter. Asset Dedication LLC now owns 291 shares of the medical equipment provider’s stock valued at $71,000 after purchasing an additional 103 shares during the last quarter. Finally, R Squared Ltd acquired a new position in STERIS in the 4th quarter valued at $78,000. Institutional investors and hedge funds own 94.69% of the company’s stock.

Insider Transactions at STERIS

In related news, SVP Cary L. Majors sold 1,682 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $217.32, for a total value of $365,532.24. Following the completion of the sale, the senior vice president now owns 11,372 shares of the company’s stock, valued at approximately $2,471,363.04. This trade represents a 12.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.14% of the company’s stock.

STERIS Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 19th. Stockholders of record on Tuesday, November 19th were given a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.04%. The ex-dividend date was Tuesday, November 19th. STERIS’s dividend payout ratio (DPR) is presently 52.05%.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.